FCA
ZNTL icon

FinTrust Capital Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

FinTrust Capital Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$62 Hold
17
– – ﹤0.01% 1358
2024
Q2 		$69 Hold
17
– – ﹤0.01% 1355
2024
Q1 		$263 Hold
17
– – ﹤0.01% 1231
2023
Q4 		$253 Hold
17
– – ﹤0.01% 1213
2023
Q3 		$335 Buy
+17
New +$432 ﹤0.01% 1184

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

FinTrust Capital Advisors's ZNTL Position: Q3 2024 in Review

FinTrust Capital Advisors held its Zentalis Pharmaceuticals (ZNTL) position steady in Q3 2024 at 17 shares worth $62. The position accounts for ﹤0.01% of the portfolio, ranked #1358.

FinTrust Capital Advisors first reported a position in ZNTL in Q3 2023 and has held it in 5 quarters since. The position peaked at $335 in Q3 2023. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • FinTrust Capital Advisors held 17 shares of Zentalis Pharmaceuticals worth $62 as of Q3 2024.
  • FinTrust Capital Advisors left its Zentalis Pharmaceuticals share count unchanged in Q3 2024.
  • Zentalis Pharmaceuticals made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1358 holding.
  • FinTrust Capital Advisors first reported a position in Zentalis Pharmaceuticals in Q3 2023 and has held it in 5 quarters since.
  • FinTrust Capital Advisors's Zentalis Pharmaceuticals position peaked at $335 in Q3 2023.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.